The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).
 
Jose Caetano Villasboas
No Relationships to Disclose
 
Craig B. Reeder
No Relationships to Disclose
 
Han W. Tun
Research Funding - Bristol-Myers Squibb (Inst)
 
Nancy L. Bartlett
Consulting or Advisory Role - ADC Therapeutics; Pfizer; Seagen
Research Funding - Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Immune Design (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Seagen (Inst)
 
Elad Sharon
No Relationships to Disclose
 
Betsy LaPlant
No Relationships to Disclose
 
Alex A. Adjei
Research Funding - Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst)
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); LAM Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)